Transplant

Mouse and non-human primate studies suggest inhibiting CD122 could enhance the efficacy of Nulojix belatacept to treat GvHD, skin graft rejection and renal transplant rejection. In a mouse model of acute GvHD, the selective T cell co-stimulation inhibitor Nulojix plus an anti-CD122 mAb decreased proliferation of CD8⁺ and CD4⁺ T cells compared with Nulojix alone. In a mouse model of acute skin graft rejection, Nulojix plus the anti-CD122 mAb increased survival compared with either agent alone. In a non-human primate model of renal transplant rejection, the combination therapy increased survival. Next steps could include testing Nulojix plus CD122 inhibition in additional models of transplant rejection...